The Women’s Health Initiative study, reported in the Journal of the National Cancer Institute, randomised 16 608 women aged 50-79 to once daily HRT (conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate as a single pill) or matching placebo for a median …